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Abstract
Sleeping sickness, also known as human African trypanosomiasis (HAT), is a neglected dis-
ease that impacts 70 million people living in 1.55 million km2 in sub-Saharan Africa. Since
the beginning of the 20th century, there have been multiple HAT epidemics in sub-Saharan
Africa, with the most recent epidemic in the 1990s resulting in about half a million HAT
cases reported between 1990 and 2015. Here we review the status of HAT disease at the
current time and the toolbox available for its control. We also highlight future opportunities
under development towards novel or improved interventions.
Human African trypanosomiasis (HAT) is a neglected disease that impacts 70 million people
living in 1.55 million km2 of sub-Saharan Africa [1]. Since the beginning of the 20th century,
there have been three major HAT epidemics, the most recent in the 1990s resulting in about
500,000 HAT cases reported between 1990 and present [2,3]. The disease is caused by two
distinct subspecies of the African trypanosomes transmitted by tsetse flies (Glossina spp.: Dip-
tera). In east and southern Africa, Trypanosoma brucei rhodesiense causes the acute Rhode-
siense form of the disease, while in central and west Africa. T. b. gambiense causes the chronic
Gambiense form of the disease (about 95% of all reported HAT cases). The disease normally
affects remote rural communities where people get exposed to the bite of the tsetse during
their daily outdoor activities. Unless treated, HAT disease is normally fatal. Besides HAT,
related parasites, such as T. b. brucei, T. congolense, T. vivax, T. evansi, and T. equiperdum,
cause wasting diseases in livestock, termed animal African trypanosomiasis (AAT), which
result in major economic losses in the concerned countries [4].
An ambitious campaign led by WHO, many nongovernmental organizations (NGOs), and
a public–private partnership with Sanofi-Aventis and Bayer that donated the necessary drugs
for distribution in affected countries reduced the global incidence of Gambiense HAT to
<3,000 cases in 2015. Based on the success of the control campaign, there are now plans to
eliminate Gambiense HAT as a public health problem by 2020 [5]. Gambiense HAT is gener-
ally considered to be an anthroponosis, and hence control has relied heavily on active and/or
passive case detection and treatment programs [6]. Control of Rhodesiense HAT has been
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more complex, as disease transmission involves domestic animals, which serve as reservoirs
for parasite transmission by the tsetse vector. Hence, for Rhodesiense HAT, control of the par-
asite in the domestic reservoirs, and/or reduction of tsetse vector populations, plays a key part,
with medical interventions being used only for humanitarian purposes.
Despite extensive research into the biology of the trypanosome, the toolbox for diagnostics
and treatment of sleeping sickness had remained extremely small and plagued with difficulties
[7]. However, the recent epidemic has mobilized financial resources available for basic and
applied research, which has led to new knowledge on both parasite and tsetse vector physiol-
ogy, genetics, and genomics and expanded the prospects for translational science for sustain-
able HAT control. Below, we review some of the progress made in the last decade towards
growing the toolbox for HAT elimination.
Controlling disease in the mammalian host
Achieving disease control in the mammalian host has been difficult given the lack of mamma-
lian vaccines due to a process of antigenic variation the parasite displays in its mammalian
host. Hence, accurate diagnosis of the parasite and staging of the disease are important, partic-
ularly because of the toxicity of current drugs. Although powerful molecular diagnostics have
been developed in research settings, few have yet reached the patient or national control pro-
grams [8]. For Gambiense HAT, a sensitive and specific test is available for active serological
screening by mobile teams [9]. However, when prevalence becomes low, targeted door-to-
door surveys may become an attractive alternative to mass screening [10]. It wil also become
crucial to integrate passive case detection in fixed health centers [5]. The development of indi-
vidual rapid sero-diagnostic tests (RDTs) will certainly facilitate the involvement of fixed
health centers in passive case detection, yet their diagnostic accuracy remains uncertain [11].
Screening for T. b. rhodesiense infection still relies on clinical features in the absence of sero-
logical tests available for field use. Although recent improvements have been made to parasito-
logical confirmatory tests, their sensitivity remains insufficient in Gambiense HAT [12].
Regarding treatment, the introduction of the eflornithine-nifurtimox combination therapy
(NECT) has made treatment of Gambiense HAT safer and more efficacious [13].
Reducing vector populations
While vector control is essential for Rhodesiense HAT, it has not played a major role in Gam-
biense HAT, as it was considered too expensive and difficult to deploy in the resource-poor
settings of HAT foci. However, modelling, historical investigations, and practical interven-
tions demonstrate the significant role that vector control can play in the control of Gambiense
HAT [14, 6, 15], especially given the possibility of long-term carriage of trypanosomes in both
human and animal reservoirs [16,17]. Recent models suggest vector control will be essential if
we are to reach the set target of elimination of the disease as a public health problem by 2020
[18]. Vector control can be particularly effective at times of low endemicity during which
active surveillance campaigns may be too costly to operate, and it is, so far, the only prophy-
lactic measure existing to protect people against the infectious bite of the tsetse vector. In
addition, the use of commercially-available loop-mediated isothermal amplification (LAMP)
kits as a highly sensitive tool for xenomonitoring has also been suggested to identify potential
sleeping sickness transmission sites, especially during periods of low endemicity [19].
For vector reduction efforts, the use of Sterile Insect Technique continent-wide has been
suggested by the African Union, following the success of the eradication program in Zanzi-
bar [20]. However, the feasibility of the application of this method continent-wide has come
into question given the diversity of species that can transmit the parasite, its high cost, and
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dependence on major infrastructure such as large insectaries, irradiation facilities, and air-
planes [21]. It has been possible to modify the existing insecticide-treated targets to produce
a more cost-efficient and sustainable vector control method for use in HAT foci. Tiny tar-
gets consisting of a small square of blue cloth flanked by a similar-sized piece of black net-
ting have been shown to be efficacious and more cost-effective than traps or large targets
typically used in control campaigns for the Gambiense vector species [14, 22]. To monitor
the efficacy and sustained impact of tsetse control interventions, sensitive serological tools
are being developed using tsetse-saliva–based biomarkers [11, 23]. A major advancement
that has fueled research into the fundamental aspects of tsetse and trypanosome transmis-
sion biology has been the completion of the genome sequence of G. morsitans morsitans
[24] and five additional vector species [41]. This information has been mined to understand
the olfactory [25, 26], symbiotic [27], and reproductive [28] physiologies of tsetse, with the
goal of identifying targets suitable for population reduction efforts. Knowledge on olfactory
physiology can be harnessed to enhance the efficacy of traps and targets by identifying novel
attractants, while the obligate dependence of tsetse on their endosymbionts provides a weak
link in this vector’s ability to reproduce, both providing ideal targets for new vector control
methods.
In addition, there has been growing knowledge on the population genetics of tsetse vectors
in disease-endemic areas in Africa. This new information can help identify natural barriers to
fly dispersal and routes and hence can provide important information for field control pro-
grams that aim to reduce vector densities through traditional tools, such as traps/targets, Ster-
ile Insect Technique, or aerial sprays [29, 30].
One fundamental reason vector control methods are highly effective in tsetse is the already
low reproductive capacity this insect has due to its viviparous reproductive physiology. The
molecular and biochemical aspects of tsetse’s viviparity and its dependence on the obligate
symbiont Wigglesworthia-provided products are being unraveled. This fundamental knowl-
edge provides many new targets for interference with tsetse fecundity to reduce tsetse popula-
tions [28].
Controlling the parasite in the tsetse vector
The increased knowledge of tsetse and trypanosome genomics has also expanded knowledge
on the molecular aspects of host–parasite interactions with several practical implications. It
has been shown that an important bottleneck for parasite transmission occurs early in the
infection process in the tsetse’s midgut, characterized by a tug-of-war between trypanosome
immune modulatory activities and the tsetse’s antiparasitic immune responses [31, 32]. The
molecular details of the complex host–parasite interactions that eventually enable the try-
panosomes to colonize the flies [33, 34], followed by modulation of the fly saliva immuno-
modulatory components by parasites, and the impact of this modification on trypanosome
transmission dynamics in the host bite site favoring parasite transmission are all being unrav-
eled and provide novel points of interference for the parasite’s transmission [35, 23]. One
approach whereby the parasite infection can be eliminated from tsetse populations involves
the ability to engineer refractoriness in tsetse [36, 37]. Towards that end, one commensal
symbiont of tsetse present in the midgut, Sodalis, has been identified, and a genetic modifica-
tion system has been developed [38]. Candidate antitrypanosomal molecules have also been
identified and expressed in Sodalis to reduce trypanosome infections as a novel approach [39,
40]. Many of these early-stage fundamental discoveries have been achieved as a consequence
of the applications of–omics technologies to the field of tsetse and trypanosomes and have
opened up the feasibility of novel targets for new innovative approaches.
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Highlights
1. The Gambiense HAT epidemics that ravaged sub-Saharan Africa in the 1990s have been
controlled, leading the way to an elimination phase. The elimination of Rhodesiense HAT
poses challenges because of the vast animal reservoirs.
2. Simplification, standardization, and proper test evaluation of diagnostic tools in the target
setting should be an important focus for future development to maintain low endemicity
and to monitor disease prevalence in the post elimination phase.
3. A safe and oral drug that cures both disease stages and both disease forms is needed.
4. Control strategies will progressively shift from active case detection by mobile teams
towards passive case detection by fixed health centers.
5. The capacity built towards HAT diagnosis and treatment should be preserved at times of
low endemicity and post elimination.
6. Application of vector control alongside medical interventions will be needed to achieve the
targets within the set time frame.
7. The molecular targets discovered through parasite and tsetse genomics/genetics studies
form the pipeline for new drugs, potential antitsetse-based vaccines, and fly inhibitory com-
pounds, which should be explored as novel biological control methods.
8. The time has come for donors, private companies, and all stakeholders to commit to the
elimination of HAT, in order to avoid resurgence as seen in the past.
References
1. Simarro P.P., Cecchi G., Franco J.R., Paone M., Diarra A., Ruiz-Postigo J.A., Fevre E.M., Mattioli R.C.,
and Jannin J.G. (2012). Estimating and mapping the population at risk of sleeping sickness. PLoS Negl
Trop Dis 6, e1859. https://doi.org/10.1371/journal.pntd.0001859 PMID: 23145192
2. Barrett M.P. (1999). The fall and rise of sleeping sickness. Lancet 353, 1113–1114. https://doi.org/10.
1016/S0140-6736(98)00416-4 PMID: 10209970
3. Headrick D.R. (2014). Sleeping sickness epidemics and colonial responses in East and Central Africa,
1900–1940. PLoS Negl Trop Dis 8, e2772. https://doi.org/10.1371/journal.pntd.0002772 PMID:
24763309
4. Alsan M. (2015). The Effect of the TseTse Fly on African Development. American Economic Review
382–410.
5. Franco J.R., Simarro P.P., Diarra A., Ruiz-Postigo J.A., and Jannin J.G. (2014). The journey towards
elimination of gambiense human African trypanosomiasis: not far, nor easy. Parasitology 141, 748–
760. https://doi.org/10.1017/S0031182013002102 PMID: 24709291
6. Lehane M., Alfaroukh I., Bucheton B., Camara M., Harris A., Kaba D., Lumbala C., Peka M., Rayaisse
J.B., Waiswa C., et al. (2016). Tsetse Control and the Elimination of Gambian Sleeping Sickness. PLoS
Negl Trop Dis 10, e0004437. https://doi.org/10.1371/journal.pntd.0004437 PMID: 27128795
7. Molyneux D., Ndung’u J., and Maudlin I. (2010). Controlling Sleeping Sickness—"When Will They Ever
Learn?". PLoS Negl Trop Dis 4(5), e609. https://doi.org/10.1371/journal.pntd.0000609 PMID:
20520799
8. Buscher P., and Deborggraeve S. (2015). How can molecular diagnostics contribute to the elimination
of human African trypanosomiasis? Expert review of molecular diagnostics 15, 607–615. https://doi.
org/10.1586/14737159.2015.1027195 PMID: 25786994
9. Magnus E., Vervoort T., and Van Meirvenne N. (1978). A card-agglutination test with stained trypano-
somes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis. Annales de la
Societe belge de medecine tropicale 58, 169–176. PMID: 747425
10. Koffi M., N’Djetchi M., Ilboudo H., Kaba D., Coulibaly B., N’Gouan E., Kouakou L., Bucheton B., Solano
P., Courtin F., et al. (2016). A targeted door-to-door strategy for sleeping sickness detection in low-
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005454 April 20, 2017 4 / 6
prevalence settings in Cote d’Ivoire. Parasite 23, 51. https://doi.org/10.1051/parasite/2016059 PMID:
27849517
11. Jamonneau V., Camara O., Ilboudo H., Peylhard M., Koffi M., Sakande H., N’Dri L., Sanou D., Dama
E., Camara M., et al. (2015). Accuracy of individual rapid tests for serodiagnosis of gambiense sleeping
sickness in West Africa. PLoS Negl Trop Dis 9, e0003480. https://doi.org/10.1371/journal.pntd.
0003480 PMID: 25642701
12. Mumba Ngoyi D., Ali Ekangu R., Mumvemba Kodi M.F., Pyana P.P., Balharbi F., Decq M., Kande Betu
V., Van der Veken W., Sese C., Menten J., et al. (2014). Performance of parasitological and molecular
techniques for the diagnosis and surveillance of gambiense sleeping sickness. PLoS Negl Trop Dis 8,
e2954. https://doi.org/10.1371/journal.pntd.0002954 PMID: 24921941
13. Priotto G., Kasparian S., Mutombo W., Ngouama D., Ghorashian S., Arnold U., Ghabri S., Baudin E.,
Buard V., Kazadi-Kyanza S., et al. (2009). Nifurtimox-eflornithine combination therapy for second-stage
African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-
inferiority trial. Lancet 374, 56–64. https://doi.org/10.1016/S0140-6736(09)61117-X PMID: 19559476
14. Courtin F., Camara M., Rayaisse J.B., Kagbadouno M., Dama E., Camara O., Traore I.S., Rouamba J.,
Peylhard M., Somda M.B., et al. (2015). Reducing Human-Tsetse Contact Significantly Enhances the
Efficacy of Sleeping Sickness Active Screening Campaigns: A Promising Result in the Context of Elimi-
nation. PLoS Negl Trop Dis 9, e0003727. https://doi.org/10.1371/journal.pntd.0003727 PMID:
26267667
15. Solano P., Torr S.J., and Lehane M.J. (2013). Is vector control needed to eliminate gambiense human
African trypanosomiasis? Front Cell Infect Microbiol 3, 33. https://doi.org/10.3389/fcimb.2013.00033
PMID: 23914350
16. Ilboudo H., Jamonneau V., Camara M., Camara O., Dama E., Leno M., Ouendeno F., Courtin F.,
Sakande H., Sanon R., et al. (2011). Diversity of response to Trypanosoma brucei gambiense infections
in the Forecariah mangrove focus (Guinea): perspectives for a better control of sleeping sickness.
Microbes Infect 13, 943–952. https://doi.org/10.1016/j.micinf.2011.05.007 PMID: 21658462
17. Molyneux D.H. (1973). Animal reservoirs and Gambian trypanosomiasis. Annales de la Societe belge
de medecine tropicale 53, 605–618. PMID: 4204667
18. Rock K.S., Torr S.J., Lumbala C., and Keeling M.J. (2015). Quantitative evaluation of the strategy to
eliminate human African trypanosomiasis in the Democratic Republic of Congo. Parasit Vectors 8, 532.
https://doi.org/10.1186/s13071-015-1131-8 PMID: 26490248
19. Cunningham L.J., Lingley J.K., Haines L.R., Ndung’u J.M., Torr S.J., and Adams E.R. (2016). Illuminat-
ing the Prevalence of Trypanosoma brucei s.l. in Glossina Using LAMP as a Tool for Xenomonitoring.
PLoS Negl Trop Dis 10, e0004441. https://doi.org/10.1371/journal.pntd.0004441 PMID: 26890882
20. Kabayo J.P. (2002). Aiming to eliminate tsetse from Africa. Trends Parasitol 18, 473–475. PMID:
12473355
21. Rogers D.J., and Randolph S.E. (2002). A response to the aim of eradicating tsetse from Africa. Trends
Parasitol 18, 534–536. PMID: 12482537
22. Shaw A.P., Tirados I., Mangwiro C.T., Esterhuizen J., Lehane M.J., Torr S.J., and Kovacic V. (2015).
Costs of using "tiny targets" to control Glossina fuscipes fuscipes, a vector of gambiense sleeping sick-
ness in Arua District of Uganda. PLoS Negl Trop Dis 9, e0003624. https://doi.org/10.1371/journal.pntd.
0003624 PMID: 25811956
23. Van Den Abbeele J., Caljon G., De Ridder K., De Baetselier P., and Coosemans M. (2010). Trypano-
soma brucei modifies the tsetse salivary composition, altering the fly feeding behavior that favors para-
site transmission. PLoS Pathog 6, e1000926. https://doi.org/10.1371/journal.ppat.1000926 PMID:
20532213
24. Aksoy S., Attardo G., Berriman M., Christoffels A., Lehane M., Masiga D., and Toure Y. (2014a).
Human African trypanosomiasis research gets a boost: unraveling the tsetse genome. PLoS Negl Trop
Dis 8, e2624.
25. Macharia R., Mireji P., Murungi E., Murilla G., Christoffels A., Aksoy S., and Masiga D. (2016).
Genome-Wide Comparative Analysis of Chemosensory Gene Families in Five Tsetse Fly Species.
PLoS Negl Trop Dis 10, e0004421. https://doi.org/10.1371/journal.pntd.0004421 PMID: 26886411
26. Obiero G.F., Mireji P.O., Nyanjom S.R., Christoffels A., Robertson H.M., and Masiga D.K. (2014). Odor-
ant and Gustatory Receptors in the Tsetse Fly Glossina morsitans morsitans. PLoS Negl Trop Dis 8,
e2663. https://doi.org/10.1371/journal.pntd.0002663 PMID: 24763191
27. Michalkova V., Benoit J.B., Weiss B.L., Attardo G.M., and Aksoy S. (2014). Vitamin B6 generated by
obligate symbionts is critical for maintaining proline homeostasis and fecundity in tsetse flies. Appl Envi-
ron Microbiol 80, 5844–5853. https://doi.org/10.1128/AEM.01150-14 PMID: 25038091
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005454 April 20, 2017 5 / 6
28. Benoit J.B., Attardo G.M., Baumann A.A., Michalkova V., and Aksoy S. (2015). Adenotrophic Viviparity
in Tsetse Flies: Potential for Population Control and as an Insect Model for Lactation. Annu Rev Ento-
mol. Vol. 60:351–371
29. Aksoy S., Caccone A., Galvani A.P., and Okedi L.M. (2013). Glossina fuscipes populations provide
insights for human African trypanosomiasis transmission in Uganda. Trends Parasitol 29, 394–406.
https://doi.org/10.1016/j.pt.2013.06.005 PMID: 23845311
30. Solano P., Ravel S., and de Meeus T. (2010). How can tsetse population genetics contribute to African
trypanosomiasis control? Trends Parasitol 26, 255–263. https://doi.org/10.1016/j.pt.2010.02.006
PMID: 20202905
31. Aksoy S., Gibson W.C., and Lehane M.J. (2003). Interactions between tsetse and trypanosomes with
implications for the control of trypanosomiasis. Adv Parasitol 53, 1–83. PMID: 14587696
32. Dyer N.A., Rose C., Ejeh N.O., and Acosta-Serrano A. (2013). Flying tryps: survival and maturation of
trypanosomes in tsetse flies. Trends Parasitol 29, 188–196. https://doi.org/10.1016/j.pt.2013.02.003
PMID: 23507033
33. Aksoy E., Vigneron A., Bing X., Zhao X., O’Neill M., Wu Y.N., Bangs J.D., Weiss B.L., and Aksoy S.
(2016). Mammalian African trypanosome VSG coat enhances tsetse’s vector competence. Proc Natl
Acad Sci U S A 113, 6961–6966. https://doi.org/10.1073/pnas.1600304113 PMID: 27185908
34. Mantilla B.S., Marchese L., Casas-Sanchez A., Dyer N.A., Ejeh N., Biran M., Bringaud F., Lehane M.J.,
Acosta-Serrano A., and Silber A.M. (2017). Proline Metabolism is Essential for Trypanosoma brucei
brucei Survival in the Tsetse Vector. PLoS Pathog 13, e1006158. https://doi.org/10.1371/journal.ppat.
1006158 PMID: 28114403
35. Caljon G., Van Den Abbeele J., Sternberg J.M., Coosemans M., De Baetselier P., and Magez S.
(2006). Tsetse fly saliva biases the immune response to Th2 and induces anti-vector antibodies that are
a useful tool for exposure assessment. Int J Parasitol 36, 1025–1035. https://doi.org/10.1016/j.ijpara.
2006.05.002 PMID: 16777113
36. Aksoy S., Weiss B.L., and Attardo G.M. (2014b). Trypanosome Transmission Dynamics in Tsetse. Curr
Opin Insect Sci 3, 43–49.
37. Weiss B., and Aksoy S. (2011). Microbiome influences on insect host vector competence. Trends Para-
sitol 27, 514–522. https://doi.org/10.1016/j.pt.2011.05.001 PMID: 21697014
38. Aksoy S., Weiss B., and Attardo G. (2008). Paratransgenesis applied for control of tsetse transmitted
sleeping sickness. Adv Exp Med Biol 627, 35–48. https://doi.org/10.1007/978-0-387-78225-6_3 PMID:
18510012
39. De Vooght L., Caljon G., De Ridder K., and Van Den Abbeele J. (2014). Delivery of a functional anti-try-
panosome Nanobody in different tsetse fly tissues via a bacterial symbiont, Sodalis glossinidius. Microb
Cell Fact 13, 156. https://doi.org/10.1186/s12934-014-0156-6 PMID: 25376234
40. De Vooght L., Caljon G., Stijlemans B., De Baetselier P., Coosemans M., and Van den Abbeele J.
(2012). Expression and extracellular release of a functional anti-trypanosome Nanobody(R) in Sodalis
glossinidius, a bacterial symbiont of the tsetse fly. Microb Cell Fact 11, 23. https://doi.org/10.1186/
1475-2859-11-23 PMID: 22335892
41. International Glossina Genome Initiative, (2014). Genome sequence of the tsetse fly (Glossina morsi-
tans): vector of African trypanosomiasis. Science 344, 380–386. https://doi.org/10.1126/science.
1249656 PMID: 24763584
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005454 April 20, 2017 6 / 6
